No immediate catalyst. Monitor for any future equity issuances under the new plan or authorized share increase, which could dilute existing holders. The doubling of authorized shares provides flexibility but signals no near-term capital need.
Price Chart
Executive Summary
Spero Therapeutics filed an 8-K reporting shareholder approval to double authorized common shares from 120M to 240M and adopt a new 2026 Stock Incentive Plan authorizing up to 12.9M shares. These are routine post-annual-meeting governance actions with no immediate financial impact or operational changes.
Key Facts
- Shareholders approved amendment to increase authorized common shares from 120,000,000 to 240,000,000.
- Shareholders approved the 2026 Stock Incentive Plan, authorizing up to 12,895,866 shares for issuance.
- Annual meeting held June 23, 2026; quorum of 70.91% of outstanding shares present.
- Directors Milind Deshpande and Kathleen Tregoning were reelected as Class III directors.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2026.
Financial Impact
No immediate financial impact; potential future dilution from up to 12.9M new shares under the equity plan, but no current issuance.
Risk Factors
- Potential dilution if the company issues shares under the new incentive plan or authorized increase.
- No operational or financial updates in this filing; stock may drift on lack of news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-283033 |
| Document: d86736dex31.htm | 0001193125-26-283033 |
| Document: 0001193125-26-283033-index-headers.html | 0001193125-26-283033 |
| Document: 0001193125-26-283033-index.html | 0001193125-26-283033 |
| Document: 0001193125-26-283033.txt | 0001193125-26-283033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.20 (−5.75%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 28, 2026 4w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.20 (−3.63%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.20 (−47.12%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.20 (−44.42%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.20 (−43.36%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.20 (−56.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access